Key facts
- Nexosome Oncology’s last known valuation is $19.3M (Jan 2026).
- It has raised $10.8M; the latest was Seed Round ($6.8M) in Jan 2026.
- Notable investors include Keyhorse Capital, OCA Ventures, TRCM Fund, VisionTech Partners, XLerateHealth.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Nexosome Oncology
- ·The full record, as it builds
Funding rounds
No funding rounds for Nexosome Oncology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nexosome Oncology
Developer of exosome-based diagnostics designed for various cancer detection. The company specializes in tumor monitoring, utilizing blood-derived exosomes to assess the response to chemotherapy and radiation, enabling healthcare providers to gain advanced tumor intelligence and determine the most effective approach to treating the tumor.
- Sector
- Healthcare
- HQ
- Lexington, KY, United States
- Founded
- 2021
- Employees
- 10
- Website
- nexosome-oncology.com/
- Ownership
- Privately Held (backing)
Nexosome Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nexosome Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nexosome Oncology in its N-PORT filings yet. We sweep new filings monthly.